跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,105 条关于
“RATIONALE-305”
全部
8,105
临床试验
3,431
药物
2,206
机构
294
资讯
2,174
去年
European Commission Approves Tislelizumab Plus Chemotherapy for ESCC and GEJ Cancer
去年
Tislelizumab Plus Chemotherapy Poised for EU Approval in Gastric, GEJ Adenocarcinoma, and ESCC
去年
FDA Approves Tevimbra Plus Chemotherapy for First-Line Treatment of Gastric and GEJ Adenocarcinoma
去年
FDA Advisory Committee Recommends Against Checkpoint Inhibitors for Certain Gastroesophageal Cancers
去年
PD-L1 Expression Thresholds in Gastrointestinal Cancers Under Scrutiny for PD-1 Inhibitor Efficacy
9天前
DeLLphi-305: Durvalumab Plus Tarlatamab Hits Overall Survival in First-Line ES-SCLC Maintenance
去年
Latigo Bio Doses First Participant in Phase 1 Trial of Non-Opioid Pain Drug LTG-305
去年
PDS Biotech Presents Trial Design of PDS01ADC Plus Enzalutamide for Recurrent Prostate Cancer
去年
FDA's PD-1 Inhibitor Label Restrictions Spark Legal and Market Access Concerns
2个月前
Aethlon Medical Identifies Novel Long COVID Biomarker, Strengthening Rationale for Hemopurifier® Platform
第 1 页,共 218 页
上一页
下一页